Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehdi Brahmi

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 1, 2021
Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG "ANITA"Patrick Schöffski, Maud Toulmonde, Anna Estival, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2019
Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas)Roberta Sanfilippo, Robin L Jones, Jean-Yves Blay, et al.
British Journal of Cancer|October 8, 2024
Role of <sup>18</sup>F-FDG-PET/CT in the initial staging of very high-risk Ewing Sarcoma in a prospective multicentric Phase II Study: Is there still a place for bone marrow sampling?Nina Jehanno, Nadège Corradini, Nathalie Gaspar, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETOJean-Yves Blay, Nicolas Penel, Maud Toulmonde, et al.
Cancer Medicine|December 20, 2022
Patterns of care and outcome of CIC-rearranged sarcoma patients: A nationwide study of the French sarcoma groupMehdi Brahmi, Nathalie Gaspar, Justine Gantzer, et al.
Cancer Research Communications|June 11, 2026
Predicting clinical sensitivities of PDGFRA exon 18 mutations to imatinib and avapritinib to optimize gastrointestinal stromal tumor treatmentHomma M Khosroyani, Alina Teuber, Ajia Town, et al.
Cancers|September 9, 2023
Evolution of Patterns of Care and Outcomes in the Real-Life Setting for Patients with Metastatic GIST Treated in Three French Expert Centers over Three DecadesMaud Toulmonde, Derek Dinart, Mehdi Brahmi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2021
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III StudyYoon-Koo Kang, Suzanne George, Robin L Jones, et al.
International Journal of Cancer|July 24, 2025
Metastatic chondrosarcoma, patterns of care, and outcomes of patients in a real-life national setting over a decadeColine Ducrot, Derek Dinart, Mathilde Reich, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2026
Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma groupEva Kalfala, Alexandra Meurgey, Clémence Hénon, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
European Journal of Cancer (Oxford, England : 1990)|June 1, 2021
Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG "ANITA"Patrick Schöffski, Maud Toulmonde, Anna Estival, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2019
Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas)Roberta Sanfilippo, Robin L Jones, Jean-Yves Blay, et al.
British Journal of Cancer|October 8, 2024
Role of <sup>18</sup>F-FDG-PET/CT in the initial staging of very high-risk Ewing Sarcoma in a prospective multicentric Phase II Study: Is there still a place for bone marrow sampling?Nina Jehanno, Nadège Corradini, Nathalie Gaspar, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETOJean-Yves Blay, Nicolas Penel, Maud Toulmonde, et al.
Cancer Medicine|December 20, 2022
Patterns of care and outcome of CIC-rearranged sarcoma patients: A nationwide study of the French sarcoma groupMehdi Brahmi, Nathalie Gaspar, Justine Gantzer, et al.
Cancer Research Communications|June 11, 2026
Predicting clinical sensitivities of PDGFRA exon 18 mutations to imatinib and avapritinib to optimize gastrointestinal stromal tumor treatmentHomma M Khosroyani, Alina Teuber, Ajia Town, et al.
Cancers|September 9, 2023
Evolution of Patterns of Care and Outcomes in the Real-Life Setting for Patients with Metastatic GIST Treated in Three French Expert Centers over Three DecadesMaud Toulmonde, Derek Dinart, Mehdi Brahmi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2021
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III StudyYoon-Koo Kang, Suzanne George, Robin L Jones, et al.
International Journal of Cancer|July 24, 2025
Metastatic chondrosarcoma, patterns of care, and outcomes of patients in a real-life national setting over a decadeColine Ducrot, Derek Dinart, Mathilde Reich, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2026
Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma groupEva Kalfala, Alexandra Meurgey, Clémence Hénon, et al.
Pageof 8